Please provide your email address to receive an email when new articles are posted on . Injectable collagenase clostridium histolyticum has revolutionized treatment for Dupuytren’s contracture. In ...
Xiaflex (collagenase clostridium histolyticum) is a brand-name injection that’s prescribed for Peyronie’s disease and Dupuytren’s contracture in adults. As with other drugs, Xiaflex can cause side ...
Please provide your email address to receive an email when new articles are posted on . Researchers used online surveys to determine whether consensus could be reached among 20 hand surgeons with ...
Injection of the anti-TNF drug adalimumab into Dupuytren's disease nodules is effective in reducing nodule hardness and nodule size. Researchers at the Kennedy Institute, University of Oxford, led by ...
MALVERN, Pa., Nov. 20, 2024 /PRNewswire/ -- Endo, Inc. ("Endo") (OTCQX: NDOI) announced today that John Elway will share an update about his Dupuytren's contracture patient journey, including his ...
Treatment options for Dupuytren’s contracture include limited fasciectomy and collagenase injection, but data comparing the two approaches are lacking. New research findings are summarized in a short ...
MALVERN, PA--(Marketwire - April 28, 2009) - Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has ...
About Dupuytren's ContractureDC is a lifelong condition that may get worse over time. It's caused by a buildup of collagen in the hand, which forms a rope-like cord that pulls fingers toward the palm ...
If you’re looking at treatment options for Dupuytren’s contracture or Peyronie’s disease, you may want to learn more about Xiaflex (collagenase clostridium histolyticum). It’s a prescription drug that ...
Dupuytrens Contracture is a condition in which a person's fingers bend toward the palm and cannot be fully extended. The condition can make working, and even daily functioning, difficult. Dr. Tom ...
Researchers at the Kennedy Institute, University of Oxford, led by Professor Jagdeep Nanchahal have demonstrated the efficacy of the anti-TNF drug adalimumab for patients with early-stage Dupuytren's ...
In a new study, scientists show that anti-TNF inhibits the cells responsible for Dupuytren's disease. Researchers at the Kennedy Institute and Nuffield Department of Orthopaedics, Rheumatology and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback